Original From: Pharmtech
Thermo Fisher Scientific¡¯s new Gibco CTS Xenon Electroporation System aims to provide easier scale up for cell therapies, from clinical development to commercial manufacturing.
Thermo Fisher Scientific introduced a new large-volume electroporation system on March 16, 2022 that is intended to enable the development of cell therapies. The system¡¯s goal is to allow cell therapy developers to move more easily from clinical development to commercial manufacturing.
The Gibco CTS Xenon Electroporation System features a closed, highly flexible design to facilitate gene modifications without the use of traditional viral vectors. According to a company press release, the electroporation approach enables the introduction of a payload into a cell by temporarily increasing cell permeability; this is done using an electrical pulse.
Unlike existing large-volume cell therapy electroporation solutions on the market, Thermo Fisher¡¯s new system features programmable, flexible electroporation conditions and offers cell therapy developers full control to optimize a variety of hard-to-transfect cell types and payloads. The system can be used as a standalone technology, or it can be integrated with the Gibco CTS Rotea Counterflow Centrifugation System as part of a modular, closed, and automated cell therapy manufacturing workflow, according to Thermo Fisher.
The CTS Xenon Electroporation System can transfect up to 2.5e9 cells in 25 mL in a sterile system. This transfection capacity enables rapid and efficient non-viral transfection for clinical manufacturing applications. In addition, the system delivers up to 80% cell viability and 90% gene knockout transfection, allowing scale up from the small-volume Neon Transfection System without the need to re-optimize the electroporation parameters. Thus, the system is designed to easily transition from benchtop to clinic, according to the company.
